Moore R D, Smith C R, Holloway J J, Lietman P S
Arch Intern Med. 1986 Jun;146(6):1153-7.
To evaluate the cost-effectiveness of cefotaxime sodium at a dosage of 12 g/day vs nafcillin sodium and tobramycin sulfate for the treatment of serious infection, the hospital and physician charges of patients enrolled in a prospective, randomized, clinical trial were analyzed. For 187 patients receiving therapy empirically, mean hospital charges for the interval in which the trial antibiotics were used were $3,550 +/- $1,740 for cefotaxime and $3,160 +/- $1,990 for nafcillin and tobramycin. After adjusting for cost-generating factors, charges for cefotaxime were greater than for nafcillin and tobramycin, but the difference was not significant. For 107 patients with clinically or bacteriologically documented infection, mean charges were $3,980 +/- $1,800 for cefotaxime and $4,170 +/- $1,780 for nafcillin and tobramycin. Adjusted charges did not differ. Incremental charges for cefotaxime per additional response were $1,630 in all patients and -$820 in patients with clinically or bacteriologically documented infections.
为评估每日剂量12克的头孢噻肟钠与萘夫西林钠和硫酸妥布霉素相比治疗严重感染的成本效益，对参与一项前瞻性、随机临床试验的患者的医院费用和医生收费进行了分析。对于187例经验性接受治疗的患者，使用试验性抗生素期间的平均医院收费，头孢噻肟为3550美元±1740美元，萘夫西林和妥布霉素为3160美元±1990美元。在对成本产生因素进行调整后，头孢噻肟的收费高于萘夫西林和妥布霉素，但差异不显著。对于107例临床或细菌学确诊感染的患者，头孢噻肟的平均收费为3980美元±1800美元，萘夫西林和妥布霉素为4170美元±1780美元。调整后的收费无差异。所有患者中，头孢噻肟每增加一个有效反应的增量收费为1630美元，临床或细菌学确诊感染的患者为 -820美元。
